<DOC>
	<DOC>NCT01233869</DOC>
	<brief_summary>This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.</brief_summary>
	<brief_title>Bosutinib For Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<criteria>Males and females, 18 to 50 years old at the time of consent. Documented diagnosis of ADPKD (PKD1 or PKD2 genotypes allowed). Total kidney volume ≥ 750 cc, as measured by centrally evaluated MRI. eGFR &lt; 60 mL/min/1.73m2. Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg). Any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (PKD) therapies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
</DOC>